Patents by Inventor Linda Brockunier

Linda Brockunier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
    Patent number: 11230543
    Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Haifeng Tang, Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Yi Zang, Weidong Pan, Anthony Ogawa, Linda Brockunier, Xianhai Huang, Hongwu Wang, Rudrajit Mal, Tesfaye Biftu, Min Park, Yan Guo, Jinlong Jiang, Helen Y. Chen, Christopher W. Plummer
  • BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20200361928
    Abstract: The present invention relates to biaryl monobactam compounds of Formula I and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.
    Type: Application
    Filed: June 25, 2020
    Publication date: November 19, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Haifeng Tang, Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Yi Zang, Weidong Pan, Anthony Ogawa, Linda Brockunier, Xianhai Huang, Hongwu Wang, Rudrajit Mal, Tesfaye Biftu, Min Park, Yan Guo, Jinlong Jiang, Helen Y. Chen, Christopher W. Plummer
  • Factor XIa inhibitors
    Patent number: 10472344
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: November 12, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Anthony K. Ogawa, Linda Brockunier, James Tata, Dann L. Parker, Jr., Ming Wang
  • FACTOR XIa INHIBITORS
    Publication number: 20180370947
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
    Type: Application
    Filed: November 29, 2016
    Publication date: December 27, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Anthony K. Ogawa, Linda Brockunier, James Tata, Dann L. Parker, Jr., Ming Wang
  • BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20180339983
    Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.
    Type: Application
    Filed: December 12, 2016
    Publication date: November 29, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Haifeng Tang, Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Yi Zang, Weidong Pan, Anthony Ogawa, Linda Brockunier, Xianhai Huang, Hongwu Wang, Rudrajit Mal, Tesfaye Biftu, Min Park, Yan Guo, Jinlong Jiang, Helen Y. Chen, Christopher W. Plummer
  • Soluble guanylate cyclase activators
    Patent number: 9284301
    Abstract: The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: March 15, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Darby Schmidt, Subharekha Raghavan, John Stelmach, Jian Guo, Jonathan Groeper, Linda Brockunier, Keith Rosauer, Hong Shen, Rui Liang, Fa-Xiang Ding
  • HCV NS3 protease inhibitors
    Patent number: 8987195
    Abstract: The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: March 24, 2015
    Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.
    Inventors: Thomas Bara, Sathesh Bhat, Dipshikha Biswas, Linda Brockunier, Duane A. Burnett, Samuel Chackalamannil, Mariappan V. Chelliah, Austin Chen, Martin Clasby, Vince J. Colandrea, Zhuyan Guo, Yongxin Han, Charles Jayne, Hubert Josien, Karen Marcantonio, Shouwu Miao, Santhosh Neelamkavil, Patrick Pinto, Murali Rajagopalan, Unmesh Shah, Francisco Velazquez, Srikanth Venkatraman, Yan Xia
  • HCV NS3 PROTEASE INHIBITORS
    Publication number: 20140057836
    Abstract: The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.
    Type: Application
    Filed: August 6, 2013
    Publication date: February 27, 2014
    Inventors: Thomas BARA, Sathesh Bhat, Dipshika Biswas, Linda Brockunier, Duane Burnette, Samuel Chackalamannil, Mariappan Vasu Cheliah, Austin Chen, Martin Clasby, Vince J. Colandrea, Zhuyan Guo, Yongxin Han, Charles Jayne, Hubert Josien, Karen Marcantonio, Shouwu Miao, Santhosh Neelamkavil, Patrick Pinto, Murali Rajogopalan, Unmesh Shah, Francisco Velazquez, Srikanth Venkatraman, Yan Xia
  • SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20130012511
    Abstract: The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
    Type: Application
    Filed: March 22, 2011
    Publication date: January 10, 2013
    Inventors: Darby Schmidt, Subharekha Raghavan, John Stelmach, Jian Guo, Jonathan Groeper, Linda Brockunier, Keith Rosauer, Hong Shen, Rui Liang, Fa-Xiang Ding
  • Pyrazole derivatives, compositions containing such compounds and methods of use
    Patent number: 7799818
    Abstract: Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: September 21, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Emma R. Parmee, Yusheng Xiong, Jian Guo, Rui Liang, Linda Brockunier
  • Pyrazole amide derivatives, compositions containing such compounds and methods of use
    Patent number: 7649009
    Abstract: Pyrazole amides are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: January 19, 2010
    Assignee: Merck & Co., Inc.
    Inventors: Teresa Beeson, Linda Brockunier, Emma R. Parmee, Subharekha Raghavan
  • Substituted pyrazoles, compositions containing such compounds and methods of use
    Patent number: 7625938
    Abstract: The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: December 1, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Linda Brockunier, Jian Guo, Rui Liang, Emma R. Parmee, Subharekha Raghavan, George Scott Tria, Yusheng Xiong
  • Pyrazole derivatives, compositions containing such compounds and methods of use
    Patent number: 7598285
    Abstract: Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: October 6, 2009
    Assignee: Merck & Co., Inc
    Inventors: Emma R. Parmee, Yusheng Xiong, Jian Guo, Rui Liang, Linda Brockunier
  • PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
    Publication number: 20090176854
    Abstract: Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: March 17, 2009
    Publication date: July 9, 2009
    Inventors: Emma R. Parmee, Yusheng Xiong, Jian Guo, Rui Liang, Linda Brockunier
  • Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use
    Publication number: 20080108620
    Abstract: The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment. The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.
    Type: Application
    Filed: July 19, 2005
    Publication date: May 8, 2008
    Applicant: MERCK & CO., INC.
    Inventors: Linda Brockunier, Jian Guo, Rui Liang, Emma R. Parmee, Subharekha Raghavan, George Scott Tria, Yusheng Xiong
  • Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use
    Publication number: 20070203186
    Abstract: Pyrazole amides are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: July 1, 2005
    Publication date: August 30, 2007
    Applicant: MERCK & CO., INC.
    Inventors: Teresa Beeson, Linda Brockunier, Emma Parmee, Subharekha Raghavan
  • Dipeptidyl peptidase inhibitors for the treatment of diabetes
    Patent number: 7253172
    Abstract: Compounds having Formula I, including pharmaceutically acceptable salts and prodrugs thereof: (I) are inhibitors of the dipeptidyl peptidase-IV enzyme (DP-IV), and are useful in the treatment of DP-IV mediated diseases and conditions, such as non-insulin dependent diabetes mellitus
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: August 7, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Linda Brockunier, Emma Parmee, Ann E. Weber
  • Pyrazole derivatives, compositions containing such compounds and methods of use
    Publication number: 20070088070
    Abstract: Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: October 19, 2006
    Publication date: April 19, 2007
    Inventors: Emma Parmee, Yusheng Xiong, Jian Guo, Linda Brockunier
  • Pyrazole derivatives, compositions containing such compounds and methods of use
    Publication number: 20050272794
    Abstract: Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    Type: Application
    Filed: June 3, 2005
    Publication date: December 8, 2005
    Inventors: Emma Parmee, Yusheng Xiong, Jian Guo, Rui Liang, Linda Brockunier
  • Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
    Publication number: 20050107390
    Abstract: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    Type: Application
    Filed: March 21, 2003
    Publication date: May 19, 2005
    Inventors: Linda Brockunier, Joseph Duffy, Dooseop Kim, Emma Parmee, Ann Weber